Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Mango is a branded, compounded prescription medication developed by Mangoceuticals for the treatment of erectile dysfunction (ED). It is formulated as a mango-flavored rapid dissolve tablet (RDT) intended for oral or sublingual administration, designed to enter the bloodstream faster than traditional pills with effects starting in as little as 10–15 minutes. The drug is a combination formulation containing tadalafil, a small molecule phosphodiesterase 5 (PDE5) inhibitor that increases blood flow to the penis; oxytocin, a peptide hormone often referred to as the 'love hormone' that may enhance feelings of intimacy and arousal; and L-arginine, an amino acid that serves as a precursor to nitric oxide, supporting vasodilation. This specific formulation utilizes tadalafil to provide a duration of action of up to 36 hours.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on tadalafil + oxytocin + l-arginine.